Evidence-Based Evaluation and Selection of Essential Medicine for Township Health Centre in China: 12.antihypertensive Medicine

SHEN Jian-tong,YANG Xiao-yan,LI You-ping,WANG Li,LI Xiao,LI Hong-hao,LI Cui-cui,WANG Ying-qiang,LI Xiang-lian,YANG Zong-xia

DOI: https://doi.org/10.3969/j.issn.1672-2531.2012.08.011

2012-01-01

Abstract:Objective To evaluate and select essential antihypertensive medicine using evidence-based approaches based on the burden of disease for township health centers located in eastern,central and western regions of China.Methods By means of the approaches,criteria,and workflow set up in the second article of this series,we referred to the recommendations of evidence-based or authority guidelines from inside and outside China,collected relevant evidence from domestic clinical studies,and recommended essential medicine based on evidence-based evaluation.Data were analyzed by Review Manager(RevMan) 5.1 and GRADE profiler 3.6 to evaluate quality of evidence.Results (1) Five clinical guidelines on hypertension were included,two of which were evidence-based.(2) Totally there were nine classes and 70 antihypertensive medicines listed in the guidelines.(3) According to WHOEML(2011),NEML(2009),CNF(2010),other guidelines,and the quantity and quality of evidence,we offered a strong recommendation for nifedipine,verapamil and enalapril and a weak recommendation for hydrochlorothiazide,indapamide,spironolactone,propranolol,metoprolol and amlodipine.We made a recommendation against furosemide and timolol due to the lack of evidence from guidelines.(4) Nine recommended medicines have been marketed with the dosage forms and specifications corresponding to guidelines in China.The prices of metoprolol,amlodipine and enalapril were higher than those of other six(daily cost: metoprolol 3.80 to 7.60 yuan,amlodipine 2.16 to 4.32 yuan,and enalapril 0.86 to 6.88 yuan).As a whole,the prices of recommended antihypertensive medicine were affordable.(5) Results of domestic studies indicated that three strongly-recommended medicines(including nifedipine,verapamil and enalapril) were safe,effective,economical and applicable.Conclusion (1) We offer a strong recommendation for nifedipine,verapamil and enalapril as antihypertensive medicine and a weak recommendation for hydrochlorothiazide,indapamide,spironolactone,propranolol,metoprolol and amlodipine.(2) There is lack of high-quality evidence from relevant domestic studies,especially on long-term safety and pharmacoeconomic evidence.(3) We propose that more studies should be carried out on the safety,efficacy and pharmacoeconomics of six medicines for which we make a weak recommendation to produce high-quality local evidence.